Tag Archives: Copaxone

Pharm Exec's Brand of the Year Applauds the Old and the New

Pharm Exec’s Brand of the Year award is itself a brand with staying power — our first recipient was Merck’s Gardasil papillomavirus vaccine, which eight years later is still going strong as one of the company’s 10 top-selling products.
Posted in Global, Orphan Drugs, Strategy | Also tagged , , , , | Leave a comment

Momenta CEO Rebuffs Teva's Copaxone Defense

Momenta Pharmaceuticals’ CEO Craig Wheeler said comments made by Teva leadership about a “purported” generic of Copaxone are “kind of humorous.” Teva’s Copaxone, a multiple sclerosis drug that earns nearly $4 billion a year, is approaching patent expiry – and possible generic competition – on May 24. Assuming FDA approves a generic version of Copaxone, […]
Posted in Biotech, FDA, IP, leadership, Legal, People, pricing, R&D, Regulatory, Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta